Nivolumab/Ipilimumab Combo Approved for Advanced RCC
Apr 19, 2018
In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients.
Genitourinary Cancers
No Improved Outcomes in Prostate Cancer With ADT Plus Mitoxantrone/Prednisone
Apr 18, 2018
Combining mitoxantrone and prednisone with adjuvant androgen deprivation therapy failed to improve overall survival over ADT alone in patients with high-risk prostate cancer.
Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
Apr 16, 2018
Antibiotics administered within 30 days of starting immunotherapy reduced both PFS and OS for patients with advanced RCC and NSCLC.
Systemic Therapy for Advanced Bladder Cancer Evolves
Apr 11, 2018
Dr. Elizabeth Plimack discusses her 2018 AACR meeting presentation on recent advances in systemic therapy for bladder cancer.
Pembrolizumab Offers Better QOL vs Chemo in Advanced Urothelial Cancer
Apr 9, 2018
Pembrolizumab offered stable or improved measures of global health status and quality of life compared with chemotherapy in patients with previously treated advanced urothelial cancer.
First-Line Avelumab/Axitinib Encouraging in Advanced RCC
Apr 5, 2018
First-line combination therapy with the PD-L1 inhibitor avelumab and the VEGFR TKI axitinib yielded antitumor activity in previously untreated RCC.
Enfortumab Vedotin Granted Breakthrough Designation for Metastatic Bladder Cancer
Apr 3, 2018
The FDA has granted a Breakthrough Therapy designation to the antibody-drug conjugate enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.
No Benefit in Outcomes With Higher Resource Use in Metastatic Prostate Cancer
Mar 30, 2018
Increases in resource use were not associated with improved survival or quality of care for patients with metastatic prostate cancer, but were associated with higher healthcare costs.
Proton RT for Prostate Cancer Has Reduced Toxicity, Higher Cost vs Other RT Options
Mar 26, 2018
Proton radiation therapy offers some reduced toxicity over IMRT in patients under the age of 65 with prostate cancer, but its cost is nearly double.
Enzalutamide Granted Priority Review for Expanded Use in Prostate Cancer
Mar 21, 2018
The FDA is granting Priority Review for the expanded use of enzalutamide in nonmetastatic castration-resistant prostate cancer.